EATG » Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults

Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults

A study published in Cochrane Library assessed the effects of interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.

HIV continues to be a leading cause of morbidity and mortality, particularly in sub-Saharan Africa. Although antiretroviral drugs have helped to improve the quality of life and life expectancy of HIV-positive individuals, there is still a need to explore other interventions that will help to further reduce the disease burden. One potential strategy is the use of interleukin-2 (IL-2) in combination with antiretroviral therapy. IL-2 is a cytokine that regulates the proliferation and differentiation of lymphocytes and may help to boost the immune system.

To read the full publication, click here.

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn